Treatments received during hospitalisation
| Treated group n=86 | Control group n=86 | P value* | |
| Methylprednisolone | 86/86 (100%) | 0 (0%) | |
| Duration of methylprednisolone (days) | 5.5 (1.6) | NA | |
| Second treatment with methylprednisolone | 8/86 (9%) | 0 (0%) | |
| Tocilizumab | 37/86 (43%) | 0 (0%) | |
| Days between start of methylprednisolone and start of tocilizumab | 4.0 (4.4) | NA | |
| Anticoagulation | 0.0160 | ||
| None | 0/86 (0%) | 8/86 (9%) | |
| LMWH | 78/86 (91%) | 75/86 (87%) | |
| DOAC/NOAC | 6/86 (7%) | 2/86 (2%) | |
| Acenocoumarol | 2/86 (2%) | 1/86 (1%) | |
| Therapeutic anticoagulation | 13/86 (15%) | 7/86 (8%) | 0.1540 |
| Chloroquine | 66/86 (77%) | 68/86 (79%) | 0.7130 |
| Antibiotics | 85/86 (99%) | 86/86 (100%) | 0.3160 |
Data are mean (SD) or n/N (%).
*Calculated with t-test or χ2, as appropriate.
DOAC, direct oral anticoagulant; LMWH, low-molecular-weight heparin; NA, not applicable; NOAC, non-vitamin K antagonist oral anticoagulant.